Kodiak Sciences Inc. (KOD)

NGM – Real Time Price. Currency in USD

35.94

+1.85 (5.43%)

At close: Jun 26, 2026, 4:00 PM EDT

35.94

0.00 (0.00%)

After-hours: Jun 26, 2026, 4:38 PM EDT

16.06.2026

Kodiak Sciences: Clinical Redemption Is Turning Into Platform Leverage

Kodiak Sciences (KOD) is transitioning from past clinical disappointments to a maturing retina platform with multiple near-term catalysts. Recent GLOW2 Phase 3 success for Zenkuda in diabetic retinopathy and upcoming pivotal data for Zenkuda, KSI-501, and KSI-101 underpin a bullish outlook. KOD's current $169.5M cash position supports near-term catalysts, but additional capital will be needed for commercialization and late-stage development.

04.06.2026

Kodiak Stock Rises 35% in 3 Months: Here's What You Need to Know

KOD surges on positive phase III Zenkuda data, accelerated regulatory plans, advancing late-stage programs and a strengthened balance sheet.

28.05.2026

Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference

PALO ALTO, Calif., May 28, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that Victor Perlroth, M.D.

08.05.2026

Kodiak's Q1 Loss Wider Than Expected, Pipeline Development in Focus

KOD posts a wider Q1 loss as research & development spending rises, while positive phase III Zenkuda data accelerate the regulatory plans.

07.05.2026

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results

PALO ALTO, Calif., May 7, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ended March 31, 2026.

01.05.2026

Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences

Clinical results of KSI-101 in macular edema secondary to inflammation (MESI) from a tertiary care uveitis practice demonstrate outcomes consistent with results from the U.S. Phase 1b APEX study, supporting continued global development and expansion of the Phase 3 PEAK and PINNACLE program into Asia. Ongoing advancement of bispecific therapies in geographic atrophy and ocular inflammatory disease; preclinical data continue to support a multi-target approach to address limitations of current single-target therapies.

30.04.2026

Kodiak Sciences (KOD) Up 2% Since Last Earnings Report: Can It Continue?

Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock?

Videos

31.10.2025

Positive

The Big 3: GOOGL, KOD, FTK

Press releases

07.05.2026

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results

PALO ALTO, Calif., May 7, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ended March 31, 2026.

31.03.2026

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

PALO ALTO, Calif., March 31, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2025.

26.03.2026

Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham

Building on the success of GLOW1 and with all patients on a 6-month dosing interval, Zenkuda (tarcocimab tedromer) demonstrated superiority to sham with 62.5% of Zenkuda-treated patients achieving a ≥2-step improvement in diabetic retinopathy severity score (DRSS) compared to 3.3% of sham-treated patients (p

04.02.2026

Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026

PALO ALTO, Calif., Feb. 4, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today participation at the virtual Angiogenesis (Angiogenesis, Exudation, and Degeneration) annual meeting on February 7, 2026.

Kodiak Sciences Inc. (KOD)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Kodiak Sciences Inc. (KOD)

Kodiak Sciences: Clinical Redemption Is Turning Into Platform Leverage

Kodiak Stock Rises 35% in 3 Months: Here's What You Need to Know

Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference

Kodiak's Q1 Loss Wider Than Expected, Pipeline Development in Focus

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results

Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences

Kodiak Sciences (KOD) Up 2% Since Last Earnings Report: Can It Continue?

Videos

Press releases

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham

Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026

Kodiak Sciences: Clinical Redemption Is Turning Into Platform Leverage

Kodiak Stock Rises 35% in 3 Months: Here's What You Need to Know

Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference

Kodiak's Q1 Loss Wider Than Expected, Pipeline Development in Focus

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results

Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences

Kodiak Sciences (KOD) Up 2% Since Last Earnings Report: Can It Continue?

Videos

Press releases

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham

Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026

Search stocks

Kodiak Sciences Inc. (KOD)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Kodiak Sciences Inc. (KOD)

Kodiak Sciences: Clinical Redemption Is Turning Into Platform Leverage

Kodiak Stock Rises 35% in 3 Months: Here's What You Need to Know

Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference

Kodiak's Q1 Loss Wider Than Expected, Pipeline Development in Focus

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results

Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences

Kodiak Sciences (KOD) Up 2% Since Last Earnings Report: Can It Continue?

Videos

Press releases

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham

Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026

Kodiak Sciences: Clinical Redemption Is Turning Into Platform Leverage

Kodiak Stock Rises 35% in 3 Months: Here's What You Need to Know

Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference

Kodiak's Q1 Loss Wider Than Expected, Pipeline Development in Focus

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results

Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences

Kodiak Sciences (KOD) Up 2% Since Last Earnings Report: Can It Continue?

Videos

Press releases

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham

Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026